Zydus Cadila gets USFDA nod for lung cancer drug Osimertinib

Written by Ruchika Sharma Published On 2021-06-04T15:44:07+05:30 | Updated On 4 Jun 2021 3:44 PM IST

Zydus Cadila gets USFDA nod for lung cancer drug Osimertinib

Ahmedabad: Drugmaker, Zydus Cadila, has recently announced that the company has received tentative approval from the United States Food & Drug Administration (USFDA) to market Osimertinib Tablets in the strengths of 40 mg and 80 mg (US RLD: Tagrisso Tablets).

Osimertinib is used to treat lung cancer. It belongs to a class of drugs known as kinase inhibitors. Osimertinib works by slowing or stopping the growth of cancer cells. It binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumors.

The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.

The group now has 318 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is a global pharmaceutical company headquartered in Ahmedabad, India.

The company discovers, develops, manufactures, and markets a broad range of healthcare therapies.

Read also: Zydus Cadila introduces scratch code in critical drug packs, starts with Remdac, Virafin

zydus cadilazydus cadila newsosimertinib tabletslung cancerkinase inhibitors

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751